Riskpilot← Back to searchSign inGet full accessStrandh Dermatologi AB
ABActiveOrg 5569204711Norrlandsgatan 11Medical specialists activities · NACE 8622Est. 20132 employees
Revenue 2025
SEK 5,2M
-25% vs 2024
EBITDA margin
38.8%
-32% vs 2024
Equity ratio
80.7%
Financial strength
Net profit 2025
SEK 1,3M
-31% vs 2024
| Revenue | SEK 5,2M | -25% |
| EBITDA | SEK 2M | -32% |
| Net profit | SEK 1,3M | -31% |
| Total assets | SEK 8,9M | +9% |
| Equity | SEK 7,2M | +2% |
| Employees | 2 | — |
Legal name
Strandh Dermatologi AB
Org number
5569204711
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
28 januari 2013
Share capital
SEK 50 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva specialistvård, läkarverksamhet, medicinska konsultationer och estetiska behandlingar. Därtill skall bolaget marknadsföra och sälja hudprodukter samt äga och förvalta fastigheter.
Address
Norrlandsgatan 11
Email
sastrandh@hotmail.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 6 735 | 8 154 | 7 515 | 7 031 | 5 239 |
| Staff expenses | — | — | — | −3 495 | −2 314 |
| EBITDA | 3 184 | 3 668 | 3 188 | 3 010 | 2 032 |
| Depreciation & amort. | −27 | −29 | −27 | −79 | −98 |
| EBIT | 3 157 | 3 639 | 3 161 | 2 931 | 1 935 |
| Net financials | — | 1 | 35 | 148 | 253 |
| Profit before tax | 2 057 | 2 440 | 2 045 | 2 327 | 1 597 |
| Tax | −427 | −547 | −422 | −485 | −330 |
| Net profit | 1 630 | 1 893 | 1 623 | 1 842 | 1 268 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 6 898 | 7 240 | 7 292 | 8 137 | 8 875 |
| Equity | 5 070 | 5 987 | 6 510 | 7 022 | 7 165 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 1 558 | 984 | 513 | 1 115 | 1 710 |
| Total debt | 1 558 | 984 | 513 | 1 115 | 1 710 |
EBITDA margin
38.8%
This company
15.8%
Market median
+146% vs market
20212025
Equity ratio
80.7%
This company
38.2%
Market median
+111% vs market
20212025
Return on equity
17.7%
This company
18.4%
Market median
+4% vs market
20212025
Net profit margin
24.2%
This company
8.1%
Market median
+199% vs market
20212025
Asset turnover
0.59×
This company
1.12×
Market median
-47% vs market
20212025
Debt / equity
0.24×
This company
0.62×
Market median
+61% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
BE | Audit | 2024 |
SS Chief Executive Officer | Chief Executive Officer | 2021 |
| Former (2) | ||
PH Chief Auditor | Chief Auditor | 2021 – 2022 |
DE Audit | Audit | 2022 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2024 | |
| Former (1) | ||
| Deputy Board Member | 2021 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Strandh Dermatologi AB 
SPK Kosmetik ABBoard members of Strandh Dermatologi AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Henrik Moberg | Chief Auditor | 0 companies |
| Barbro Elisabeth Lillkaas | Audit | 0 companies |
| Dick Erik Helén | Audit | 0 companies |
| Sanna Strandh | Chief Executive Officer | 0 companies |
| Pavel Strandh | Deputy Board Member | 0 companies |
| Katja Katerina Strandh | Deputy Board Member | 0 companies |